Table 4 Pairwise meta-analyses for hematological toxicities of different CCRT regimens in the treatment of LA-NSCLC
Included studies | Comparisons | Toxicity events | Pairwise meta-analysis | |||
|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | OR (95% CI) | I2 | P | ||
Anemia | ||||||
 2 studies | A VS. B | 5/64 | 5/76 | 1.20 (0.33–4.36) | 0.0% | 0.807 |
 2 studies | F VS. I | 5/56 | 5/56 | 1.00 (0.27–3.67) | 0.0% | 0.508 |
 3 studies | K VS. R | 3/174 | 9/176 | 0.33 (0.09–1.22) | 0.0% | 0.649 |
 1 study | A VS. D | 22/272 | 16/283 | 1.47 (0.75–2.86) | NA | NA |
 1 study | A VS. E | 1/50 | 1/55 | 1.10 (0.07–18.10) | NA | NA |
 1 study | A VS. M | 1/95 | 1/96 | 1.01 (0.06–16.40) | NA | NA |
 1 study | B VS. G | 9/151 | 24/153 | 0.34 (0.15–0.76) | NA | NA |
 1 study | B VS. N | 9/151 | 13/152 | 0.68 (0.28–1.65) | NA | NA |
 1 study | D VS. H | 5/52 | 8/48 | 0.53 (0.16–1.76) | NA | NA |
 1 study | F VS. H | 2/35 | 2/31 | 0.88 (0.12–6.64) | NA | NA |
 1 study | G VS. N | 24/153 | 13/152 | 1.99 (0.97–4.07) | NA | NA |
 1 study | I VS. K | 8/88 | 7/88 | 1.16 (0.40–3.34) | NA | NA |
Leukopenia | ||||||
 2 studies | F VS. I | 13/56 | 10/56 | 1.39 (0.55–3.50) | 0.0% | 0.943 |
 2 studies | K VS. R | 2/121 | 74/122 | 0.01 (0.00–0.05) | 73.6% | 0.052 |
 1 study | A VS. D | 69/272 | 53/283 | 1.48 (0.98–2.21) | NA | NA |
 1 study | A VS. M | 29/95 | 26/96 | 1.18 (0.63–2.21) | NA | NA |
 1 study | D VS. H | 11/52 | 20/48 | 0.38 (0.16–0.90) | NA | NA |
 1 study | F VS. H | 8/35 | 19/31 | 0.19 (0.06–0.55) | NA | NA |
 1 study | I VS. K | 48/88 | 46/88 | 1.10 (0.61–1.98) | NA | NA |
 1 study | K VS. O | 1/47 | 21/60 | 0.04 (0.01–0.31) | NA | NA |
Neutropenia | ||||||
 2 studies | A VS. B | 37/64 | 23/76 | 3.16 (1.57–6.34) | 0.0% | 0.636 |
 1 study | A VS. D | 78/272 | 52/283 | 1.79 (1.20–2.66) | NA | NA |
 1 study | A VS. E | 4/50 | 1/55 | 4.70 (0.51–43.51) | NA | NA |
 1 study | B VS. G | 35/151 | 144/153 | 0.02 (0.01–0.04) | NA | NA |
 1 study | B VS. N | 35/151 | 82/152 | 0.26 (0.16–0.42) | NA | NA |
 1 study | E VS. G | 61/99 | 94/101 | 0.10 (0.04–0.26) | NA | NA |
 1 study | G VS. N | 144/153 | 82/152 | 13.66 (6.48–28.77) | NA | NA |
Thrombocytopenia | ||||||
 2 studies | A VS. B | 8/64 | 5/76 | 2.03 (0.63–6.54) | 0.0% | 0.345 |
 2 studies | F VS. I | 10/56 | 9/56 | 1.14 (0.42–3.05) | 0.0% | 0.834 |
 1 study | A VS. D | 19/272 | 15/283 | 1.34 (0.67–2.70) | NA | NA |
 1 study | A VS. E | 1/50 | 1/55 | 1.10 (0.07–18.10) | NA | NA |
 1 study | A VS. M | 1/95 | 1/96 | 1.01 (0.06–16.40) | NA | NA |
 1 study | B VS. G | 8/151 | 34/153 | 0.20 (0.09–0.44) | NA | NA |
 1 study | B VS. N | 8/151 | 18/152 | 0.42 (0.18–0.99) | NA | NA |
 1 study | D VS. H | 3/52 | 3/48 | 0.92 (0.18–4.79) | NA | NA |
 1 study | E VS. G | 2/99 | 25/101 | 0.06 (0.01–0.27) | NA | NA |
 1 study | G VS. N | 34/153 | 18/152 | 2.13 (1.14–3.96) | NA | NA |
 1 study | F VS. H | 1/35 | 1/31 | 0.88 (0.05–14.73) | NA | NA |
Febrile neutropenia | ||||||
 1 study | A VS. B | 6/31 | 5/44 | 1.87 (0.52–6.79) | NA | NA |
 1 study | A VS. D | 20/272 | 9/283 | 2.42 (1.08–5.40) | NA | NA |
 1 study | B VS. G | 5/151 | 47/153 | 0.08 (0.03–0.20) | NA | NA |
 1 study | B VS. N | 5/151 | 9/152 | 0.54 (0.18–1.66) | NA | NA |
 1 study | E VS. G | 22/99 | 39/101 | 0.45 (0.24–0.84) | NA | NA |
 1 study | G VS. N | 47/153 | 9/152 | 7.05 (3.31–15.01) | NA | NA |